Effects of repeated nicotine administration and footshock stress on rat mesoprefrontal dopamine systems: Evidence for opioid mechanisms

Neuropsychopharmacology

Volumn 23, Issue 1, 2000, Pages 79-88

  George, Tony P ^a   Verrico, Christopher D ^a   Xu, Li ^a   Roth, Robert H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Naloxone; Nicotine; Opiates; Prefrontal cortex

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; NALOXONE; NICOTINE; OPIATE PEPTIDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ELECTRIC SHOCK; IMMOBILIZATION; MALE; MENTAL STRESS; NONHUMAN; NUCLEUS ACCUMBENS; PHYSICAL STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SMOKING; SMOKING CESSATION; SUBSTANCE ABUSE;

ANIMALS; DOPAMINE; IMMOBILIZATION; MALE; NALOXONE; NARCOTIC ANTAGONISTS; NICOTINE; NICOTINIC AGONISTS; OPIOID PEPTIDES; PREFRONTAL CORTEX; RATS; STRESS;

EID: 0034081933     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00165-7     Document Type: Article

References (43)

1. Aceto M.D., Scates S.M., Ji Z., Bowman E.R. Nicotine's opioid and anti-opioid interactions. proposed role in smoking behavior Eur J Pharmacol. 248:1993;333-335.
2. Balfour D.J.K., Fagerstrom K.O. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther. 72:1996;51-81.
3. Boyd R.T. The molecular biology of neuronal nicotinic acetylcholine receptors. Crit Rev Toxicol. 27:1997;299-318.
4. Christensen M.-K., Smith D.F. Antinociceptive effects of the stereoisomers of nicotine given intrathecally in spinal rats. J Neural Transm. 80:1990;189-194.
5. Corrigall W.A., Herling S., Coen K.M. Evidence for opioid mechanisms in the behavioral effects of nicotine. Psychopharmacology. 96:1988;29-35.
6. Davenport K.E., Houdi A.A., Van Loon G.R. Nicotine protects against μ-opioid receptor antagonism by β-funaltrexamine. Evidence for nicotine-induced release of endogenous opiods in the brain Neurosci Lett. 113:1990;40.
7. Davis M., Astrachan D.I. Conditioned fear and startle magnitude. Effects of different footshock or barshock intensities used in training J Exp Psychol. 4:1978;95-103.
8. Devine D.P., Leone P., Pocock D., Wise R.A. Differential involvement of ventral tegmental mu, delta, and kappa opioid receptors in modulation of basal mesolimbic dopamine release. In vivo microdialysis studies J Pharmacol Exp Ther. 244:1993;1067-1080.
9. Eiden L.E., Giraud P., Dave J.T., Hotchkiss A.J., Affolter H. Nicotinic receptor stimulation activates enkephalin release and biosynthesis in adrenal chromaffin cell. Nature. 312:1984;661.
10. Elsworth J.D., Brittan M.S., Taylor J.R., Sladek J.R., Al-Tikriti M.S., Zea-Ponce Y., Innis R.B., Redmond D.E. Jr., Roth R.H. Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys. Cell Transpl. 5:1996;315-325.
11. Finley J.C.W., Maderdrut J.L., Petrusz P. The immunocytochemical localization of enkephalin in the central nervous system of the rat. J Comp Neurol. 198:1981;541-565.
12. George T.P., Verrico C.D., Roth R.H. Effects of nicotine and stress on rat mesoprefrontal dopamine systems. Evidence for opiate mechanisms Soc Neurosci Abstr. 23:1997;1359.
13. George T.P., Verrico C.D., Roth R.H. Effects of repeated nicotine pre-treatment on mesoprefrontal dopaminergic and behavioral responses to acute footshock stress. Brain Res. 801:1998;36-49.
14. Gorelick D.A., Rose J., Jarvik M.E. Effects of naloxone on cigarette smoking. J Subst Abuse. 1:1988;153-159.
15. Henningfield J.E., Schuh L.M., Jarvik M.E. Pathophysiology of tobacco dependence. Bloom F.E., Hupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;1715-1729 Raven Press, New York.
16. Hildebrand B.E., Nomikos G.G., Bondjers C., Nisell M., Svensson T.H. Behavioral manifestations of the nicotine abstinence syndrome in the rat. Peripheral versus central mechanisms Psychopharmacology. 129:1997;348-356.
17. Hildebrand B.E., Nomikos G.G., Panagis G., Hertel P., Schilstrom B., Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res. 779:1998;214-225.
18. Horger B.A., Roth R.H. The role of mesoprefrontal dopamine neurons in stress. Crit Rev Neurobiol. 10:1996;395-418.
19. Houdi A.A., Pierzchala K., Marson M., Palkovits M., Van Loon G.R. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides. 12:1991;161.
20. Kalivas P.W., Abhold R. Enkephalin release into the ventral tegmental area in response to stress. Modulation of mesocorticolimbic dopamine Brain Res. 414:1987;339-348.
21. Karras A., Kane J.M. Naloxone reduces cigarette smoking. Life Sci. 27:1980;1541-1545.
22. Khachaturian H., Lewis M.E., Watson S.J. Enkephalin systems in diencephalon and brainstem of the rat. J Comp Neurol. 220:1983;310-320.
23. Krishnan-Sarin S., Rosen M.I., O'Malley S.S. Evidence for an opioid component in nicotine dependence. Arch Gen Psychiatry. 56:1999;663-668.
24. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the phenol-folin reagent. J Biol Chem. 193:1957;265-275.
25. Malin D.H., Lake J.R., Carter V.A., Cunningham J.S., Wilson O.B. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology. 112:1993;339-342.
26. Malin D.H., Lake J.R., Payne M.C., Short P.E., Carter V.A., Cunningham J.S., Wilson O.B. Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacol Biochem Behav. 53:1996;81-85. a.
27. Malin D.H., Lake J.R., Short P.E., Blossman J.B., Lawless B.A., Schopen C.K., Sailer E.E., Burgess K., Wilson O.B. Nicotine abstinence syndrome precipiated by an analog of neuropeptide FF. Pharmacol Biochem Behav. 54:1996;581-585. b.
28. McGehee D.S., Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Ann Rev Physiol. 57:1995;521-546.
29. Miller J.D., Speciale S.G., McMillen B.A., German D.C. Naloxone antagonism of stress-induced augmentation of frontal cortex dopamine metabolism. Eur J Pharmacol. 98:1984;437-439.
30. Nemeth-Coslett R., Griffiths R.R. Naloxone does not affect cigarette smoking. Psychopharmacology. 89:1986;261-264.
31. Nisell M., Nomikos G.G., Hertel P., Panagis G., Svennson T.H. Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse. 22:1996;369-381.
32. O'Malley SS, Krishnan-Sarin S, Meandzija B (1997): Naltrexone treatment of nicotine dependence: A preliminary study. Presented at the Annual Meeting of the American Psychiatric Association, San Diego, CA, May 1997.
33. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed:1986;Academic Press, San Diego, CA.
34. Pidoplichko V.I., DeBias M., Williams J.T., Dani J.A. Nicotine activates and desensitizes midbrain dopamine neurons. Nature. 390:1997;401-404.
35. Pomerleau O.F., Fertig J.B., Seyler L.E., Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology. 81:1983;61-67.
36. Sesack S.R., Pickel V.M. Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area. Multiple substrates for opiate-dopamine interactions J Neurosci. 12:1992;1335-1350.
37. Shieh K.-R., Pan J.-T. Nicotinic control of tuberoinfundibular dopaminergic neuron activity and prolactin secretion. Diurnal rhythm and involvement of endogenous opiodergic system Brain Res. 756:1997;266-272.
38. Spanagel R., Herz A., Shippenberg T.S. Opposing tonically active endogenous opiate systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA. 89:1992;2046-2050.
39. Sutherland G., Stapleton J.A., Russell M.A., Feyerabend C. Naltrexone, smoking behavior and cigarette withdrawal. Psychopharmacology. 120:1995;418-425.
40. Tam S.-Y. Regulation of Mesoprefrontal Dopamine Neurons. Ph.D. Thesis. 1988;Yale University, New Haven, CT.
41. Thierry A.M., Tassin J.-P., Blanc G., Glowinski J. Selective activation of the mesocortical dopamine system by stress. Nature. 263:1976;2420-2424.
42. Vezina P., Blanc G., Glowinski J., Tassin J.-P. Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields. Effects of acute and repeated injections J Pharmacol Exp Ther. 261:1992;484-490.
43. Zarrindast M.-R., Farzin D. Nicotine attenuates naloxone-induced jumping behavior in morphine-dependent mice. Eur J Pharmacol. 298:1996;1-6.